WallStSmart

ICICI Bank Limited (IBN)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ICICI Bank Limited generates 39167% more annual revenue ($2.17T vs $5.54B). RMD leads profitability with a 27.4% profit margin vs 24.9%. IBN appears more attractively valued with a PEG of 0.53. IBN earns a higher WallStSmart Score of 81/100 (A-).

IBN

Exceptional Buy

81

out of 100

Grade: A-

Growth: 8.0Profit: 7.5Value: 7.0Quality: 5.0

RMD

Strong Buy

73

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 5.3Quality: 8.3
Piotroski: 6/9Altman Z: 4.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for IBN.

RMDOvervalued (-13.1%)

Margin of Safety

-13.1%

Fair Value

$229.58

Current Price

$206.76

$22.82 premium

UndervaluedFair: $229.58Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IBN6 strengths · Avg: 9.0/10
Operating MarginProfitability
33.3%10/10

Strong operational efficiency at 33.3%

Revenue GrowthGrowth
66.9%10/10

Revenue surging 66.9% year-over-year

Market CapQuality
$95.83B9/10

Large-cap with strong market position

Profit MarginProfitability
24.9%9/10

Keeps 25 of every $100 in revenue as profit

PEG RatioValuation
0.538/10

Growing faster than its price suggests

P/E RatioValuation
17.0x8/10

Attractively priced relative to earnings

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.3%10/10

Strong operational efficiency at 35.3%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.3%9/10

Every $100 of equity generates 25 in profit

Profit MarginProfitability
27.4%9/10

Keeps 27 of every $100 in revenue as profit

Areas to Watch

IBN0 concerns · Avg: 0/10

No major concerns identified

RMD0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : IBN

The strongest argument for IBN centers on Operating Margin, Revenue Growth, Market Cap. Profitability is solid with margins at 24.9% and operating margin at 33.3%. Revenue growth of 66.9% demonstrates continued momentum.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.4% and operating margin at 35.3%. Revenue growth of 10.8% demonstrates continued momentum.

Bear Case : IBN

No major red flags identified for IBN, but monitor valuation.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Key Dynamics to Monitor

IBN profiles as a growth stock while RMD is a mature play — different risk/reward profiles.

RMD carries more volatility with a beta of 0.84 — expect wider price swings.

IBN is growing revenue faster at 66.9% — sustainability is the question.

Monitor BANKS - REGIONAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

IBN scores higher overall (81/100 vs 73/100), backed by strong 24.9% margins and 66.9% revenue growth. Both earn "Exceptional Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ICICI Bank Limited

FINANCIAL SERVICES · BANKS - REGIONAL · USA

ICICI Bank Limited offers various banking products and financial services in India and internationally. The company is headquartered in Mumbai, India.

Visit Website →

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?